



Rajasthan Medical Services Corporation Limited

Gandhi Block, SwasthyaBhawan, Tilak Marg, C-Scheme, Jaipur-302005 (Raj.)

Phone No: 0141-2228066 ,2228064 Fax No. 0141-2228065 Website: <http://rmsc.health.rajasthan.gov.in>

CIN:U24232RJ2011SGC035067

E_mail :edprocurement@gmail.com, and rmse@nic.in

Ref. No.:- F.02(271)/RMSCL/PROCUREMENT/DRUG/NIB-13/2019/1370

Dated:-26.11.19

Corrigendum – III

Subject:-Amendments in BOQ/ technical specification/Packing Unit/Quantity

Ref.:- Prebid meeting dated 21.10.2019 and NIB No. F.02(271)/RMSCL/PROCUREMENT / DRUG/NIB-13/2019/1127 Dated:-15.10.2019 (Technical bid opening due on dated – 10.12.2019)

| S. No | Existing condition / technical specification/Packing Unit/Quantity (clause no.) | Amended condition / technical specification/ Packing Unit/Quantity/Shelf Life/Date Extension (clause no.). | | | | | | | | | | | | |
|----------|---|--|---------------------------------|-----|--|-----|--|--|----------|--|-----|--|-----|--|
| 1. | <p>Clause 2(c) ELIGIBILITY CRITERIA Clause 5 (i) (j) TECHNICAL BID Annexure-XV Ref. Clause No. 2 (c)</p> <table border="1"> <thead> <tr> <th>Code No.</th> <th>Name of item with specification</th> </tr> </thead> <tbody> <tr> <td>500</td> <td>Acetylcystine Solution USP (Injection) 200 mg/ml</td> </tr> <tr> <td>642</td> <td>Oseltamivir Phosphate for Oral Suspension IP 12 mg/ml (Each ml contains 12 mg Oseltamivir base after reconstitution)</td> </tr> </tbody> </table> <p>Clause 2(b) ELIGIBILITY CRITERIA (a) Average Annual turnover (for drugs and medicines including Surgical and sutures Business) in the last three financial years 2015-16, 2016-17 & 2017-18 or 2016-17, 2017-18 & 2018-19 should not be less than Rs. 20 Crores. For MSME units of Rajasthan, the average annual turnover in the last three financial years 2015-16, 2016-17 & 2017-18 or 2016-17, 2017-18 & 2018-19 should not be less than Rs. 2 Crore. For drug items falling in the category of Disinfectants & Antiseptics, Eye preparations and Ear drops etc (Item code 332) bidder's firms average annual turnover of last three financial years should not be less than Rs. 2 Crore.</p> | Code No. | Name of item with specification | 500 | Acetylcystine Solution USP (Injection) 200 mg/ml | 642 | Oseltamivir Phosphate for Oral Suspension IP 12 mg/ml (Each ml contains 12 mg Oseltamivir base after reconstitution) | <p>Clause 2(c) ELIGIBILITY CRITERIA Clause 5 (i) (j) TECHNICAL BID Annexure-XV Ref. Clause No. 2 (c)</p> <table border="1"> <thead> <tr> <th>Code No.</th> <th>Relaxation in Condition of Market Standing Certificate and Performance Statement</th> </tr> </thead> <tbody> <tr> <td>500</td> <td>Market Standing Certificate of one year and Performance Statement having at least one batch in any of last three financial years acceptable.</td> </tr> <tr> <td>642</td> <td></td> </tr> </tbody> </table> <p>Clause 2(b) ELIGIBILITY CRITERIA (a) Average Annual turnover (for drugs and medicines including Surgical and sutures Business) in the last three financial years 2015-16, 2016-17 & 2017-18 or 2016-17, 2017-18 & 2018-19 should not be less than Rs. 20 Crores. For MSME units of Rajasthan, the average annual turnover in the last three financial years 2015-16, 2016-17 & 2017-18 or 2016-17, 2017-18 & 2018-19 should not be less than Rs. 2 Crore. For drug items falling in the category of Disinfectants & Antiseptics, Eye preparations and Ear drops etc (Item code 332) bidder's firms average annual turnover of last three financial years should not be less than Rs. 2 Crore.</p> <p><u>For item code 175, bidder's firm average annual turnover of last three financial years should not be less than Rs. 5 Cr.</u></p> | Code No. | Relaxation in Condition of Market Standing Certificate and Performance Statement | 500 | Market Standing Certificate of one year and Performance Statement having at least one batch in any of last three financial years acceptable. | 642 | |
| Code No. | Name of item with specification | | | | | | | | | | | | | |
| 500 | Acetylcystine Solution USP (Injection) 200 mg/ml | | | | | | | | | | | | | |
| 642 | Oseltamivir Phosphate for Oral Suspension IP 12 mg/ml (Each ml contains 12 mg Oseltamivir base after reconstitution) | | | | | | | | | | | | | |
| Code No. | Relaxation in Condition of Market Standing Certificate and Performance Statement | | | | | | | | | | | | | |
| 500 | Market Standing Certificate of one year and Performance Statement having at least one batch in any of last three financial years acceptable. | | | | | | | | | | | | | |
| 642 | | | | | | | | | | | | | | |

| S. No | Existing condition / technical specification/Packing Unit/Quantity (clause no.) | Amended condition / technical specification/ Packing Unit/Quantity/Shelf Life/Date Extension (clause no.). | | | | | | | | | | | | | | | | | | | | | | | | |
|----------|--|--|---------------------------------|--------------|-----|-------------------------------|---------------|----------|---------------------------------|-----|--|-----|--|---|----------|---------------------------------|--------------|-----|-------------------------------|---|----------|---------------------------------|-----|--|-----|---|
| 4. | <p>Annexure – VIII (List of Drugs with Specifications) and BoQ</p> <table border="1"> <thead> <tr> <th>Code No.</th> <th>Name of item with specification</th> <th>Packing Unit</th> </tr> </thead> <tbody> <tr> <td>175</td> <td>Human Albumin Solution IP 20%</td> <td>100 ml Bottle</td> </tr> </tbody> </table> <table border="1"> <thead> <tr> <th>Code No.</th> <th>Name of item with specification</th> </tr> </thead> <tbody> <tr> <td>303</td> <td>Human Anti D Immunoglobulin Injection IP 300mcg (IM use)</td> </tr> <tr> <td>304</td> <td>Human Anti D Immunoglobulin IP 150 mcg</td> </tr> </tbody> </table> | Code No. | Name of item with specification | Packing Unit | 175 | Human Albumin Solution IP 20% | 100 ml Bottle | Code No. | Name of item with specification | 303 | Human Anti D Immunoglobulin Injection IP 300mcg (IM use) | 304 | Human Anti D Immunoglobulin IP 150 mcg | <p>Annexure – VIII (List of Drugs with Specifications) and BoQ</p> <table border="1"> <thead> <tr> <th>Code No.</th> <th>Name of item with specification</th> <th>Packing Unit</th> </tr> </thead> <tbody> <tr> <td>175</td> <td>Human Albumin Solution IP 20%</td> <td>100 ml Bottle/ flexible closed System Bag 20% 100ml</td> </tr> </tbody> </table> <table border="1"> <thead> <tr> <th>Code No.</th> <th>Name of item with specification</th> </tr> </thead> <tbody> <tr> <td>303</td> <td>Human Anti D Immunoglobulin Injection IP 300mcg (IM use) / Human Anti D Immunoglobulin Injection 300mcg (IM use)</td> </tr> <tr> <td>304</td> <td>Human Anti D Immunoglobulin IP 150 mcg/ Human Anti D Immunoglobulin 150 mcg</td> </tr> </tbody> </table> | Code No. | Name of item with specification | Packing Unit | 175 | Human Albumin Solution IP 20% | 100 ml Bottle/ flexible closed System Bag 20% 100ml | Code No. | Name of item with specification | 303 | Human Anti D Immunoglobulin Injection IP 300mcg (IM use) / Human Anti D Immunoglobulin Injection 300mcg (IM use) | 304 | Human Anti D Immunoglobulin IP 150 mcg/ Human Anti D Immunoglobulin 150 mcg |
| Code No. | Name of item with specification | Packing Unit | | | | | | | | | | | | | | | | | | | | | | | | |
| 175 | Human Albumin Solution IP 20% | 100 ml Bottle | | | | | | | | | | | | | | | | | | | | | | | | |
| Code No. | Name of item with specification | | | | | | | | | | | | | | | | | | | | | | | | | |
| 303 | Human Anti D Immunoglobulin Injection IP 300mcg (IM use) | | | | | | | | | | | | | | | | | | | | | | | | | |
| 304 | Human Anti D Immunoglobulin IP 150 mcg | | | | | | | | | | | | | | | | | | | | | | | | | |
| Code No. | Name of item with specification | Packing Unit | | | | | | | | | | | | | | | | | | | | | | | | |
| 175 | Human Albumin Solution IP 20% | 100 ml Bottle/ flexible closed System Bag 20% 100ml | | | | | | | | | | | | | | | | | | | | | | | | |
| Code No. | Name of item with specification | | | | | | | | | | | | | | | | | | | | | | | | | |
| 303 | Human Anti D Immunoglobulin Injection IP 300mcg (IM use) / Human Anti D Immunoglobulin Injection 300mcg (IM use) | | | | | | | | | | | | | | | | | | | | | | | | | |
| 304 | Human Anti D Immunoglobulin IP 150 mcg/ Human Anti D Immunoglobulin 150 mcg | | | | | | | | | | | | | | | | | | | | | | | | | |

Note:-

- It may be noted that if any further amendments are issued then a corrigendum will be published and informed.
- Rest of the terms and conditions will remain the same.




Executive Director (Proc.)
RMSCL